Gian Matteo Pica

Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA)

Emmanuel Bachy, Vincent Camus, Catherine Thiéblemont et al. · Journal of Clinical Oncology · 2021 · 192 citations · Full text

Medicine, Oncology, Pharmacotherapy +8

High total metabolic tumor volume at baseline predicts survival independent of response to therapy

Laëtitia Vercellino, Anne‐Ségolène Cottereau, Olivier Casasnovas et al. · Blood · 2020 · 185 citations · Full text

Medicine, Cancer Biology, Oncology +12

Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R²) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma

Franck Morschhauser, Loretta J. Nastoupil, Pierre Feugier et al. · Journal of Clinical Oncology · 2022 · 68 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Clinicopathological features and survival in EBV-positive diffuse large B-cell lymphoma not otherwise specified

Estelle Bourbon, Delphine Maucort‐Boulch, Juliette Fontaine et al. · Blood Advances · 2021 · 67 citations · Full text

Medicine, Hematology, Oncology +11

Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial

Vincent Camus, Catherine Thiéblemont, Philippe Gaulard et al. · Journal of Clinical Oncology · 2024 · 42 citations · Full text

Medicine, Oncology, Pharmacotherapy +5